Cowen analyst Joshua Jennings raised the firm’s price target on TransMedics to $70 from $60 and keeps an Outperform rating on the shares. The analyst said after hosting a physician expert call with a veteran lung transplant surgeon at a high-volume U.S. transplant center, he sees the potential to expand donor lung utilization Is real and full reimbursement for OCS Lung is routine.
Published first on TheFly